Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving Average – What’s Next?

Spero Therapeutics, Inc. (NASDAQ:SPRO)’s stock price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.47 and traded as low as $2.20. Spero Therapeutics shares last traded at $2.21, with a volume of 433,658 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Wall Street Zen lowered Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce”.

Spero Therapeutics Price Performance

The firm has a fifty day simple moving average of $2.61 and a 200-day simple moving average of $2.47. The firm has a market cap of $127.96 million, a P/E ratio of 9.21 and a beta of 1.45.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. The firm had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.26 million. Spero Therapeutics had a return on equity of 35.58% and a net margin of 24.90%.

Insider Transactions at Spero Therapeutics

In related news, insider Esther Rajavelu sold 25,240 shares of Spero Therapeutics stock in a transaction on Monday, May 4th. The shares were sold at an average price of $2.51, for a total value of $63,352.40. Following the completion of the sale, the insider owned 986,851 shares of the company’s stock, valued at approximately $2,476,996.01. This trade represents a 2.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. GSK plc acquired a new position in Spero Therapeutics during the 4th quarter valued at about $21,414,000. Vanguard Group Inc. lifted its position in shares of Spero Therapeutics by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company’s stock worth $3,741,000 after buying an additional 39,474 shares in the last quarter. State Street Corp lifted its position in shares of Spero Therapeutics by 10.1% during the 4th quarter. State Street Corp now owns 210,151 shares of the company’s stock worth $490,000 after buying an additional 19,200 shares in the last quarter. Ionic Capital Management LLC boosted its stake in shares of Spero Therapeutics by 39.2% in the 3rd quarter. Ionic Capital Management LLC now owns 208,725 shares of the company’s stock worth $392,000 after buying an additional 58,725 shares during the last quarter. Finally, Intrepid Family Office LLC boosted its stake in shares of Spero Therapeutics by 50.0% in the 4th quarter. Intrepid Family Office LLC now owns 165,000 shares of the company’s stock worth $384,000 after buying an additional 55,000 shares during the last quarter. 25.60% of the stock is owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.